mounjaro vs semaglutide for weight loss GLP-1 Ozempic vs Wegovy vs is semaglutide in mounjaro What's

The SURPASS phase III clinical trials for tirzepatide involve more than 13,000 patients with T2D and aim to gain a better understanding of its efficacy and safety (ClinicalTrials.gov Identifier: NCT04255433)

Individuals with minimal weight to lose (BMI under 27 kg/m without comorbidities) do not meet clinical criteria for pharmacological weight loss treatment

Unopened pens must be refrigerated

Routine thyroid monitoring (such as calcitonin testing or ultrasound) is not recommended for patients without specific risk factors, as this has not been shown to be beneficial and may lead to unnecessary interventions

Opisani efekti GIP-a su u vezi sa masnim tkivom, jer ovaj hormon stimulie adipogenezu ili lipogenezu (formiranje masnog tkiva), poboljava sposobnost insulina da podstie skladitenje masti, inhibira lipolizu (smanjuje mogunost sagorevanja masti), ali i poveava protok krvi u masno tkivo, to potencijalno dovodi do akumulacije masti

For CKD staging, use E11.22 (stage 12), E11.12 (stage 3), E11.13 (stage 4), or E11.14 (stage 5/ESRD), always paired with the corresponding N18.x code